Table 2.
Seroconversion rates by poliovirus type in the per-protocol population of each vaccine schedule group
| Poliovirus type 1n/N (% [95% CI]) | Poliovirus type 2 n/N (% [95% CI]) | Poliovirus type 3 n/N (% [95% CI]) | |
|---|---|---|---|
| Three IPV group at week 18 after two doses | 172/180 (96% [91·4–98·1]) | 160/180 (88% [83·4–93·1]) | 169/18093·9 (89·3–96·9) |
| Three IPV group at week 40 after three doses | 178/178 (100% [97·9–100]) | 178/178 (100% [97·9–100]) | 178/178100 (97·9–100) |
| Two IPV group at week 40 after two doses | 152/154 (99% [95·4–99·8]) | 153/154 (99% [96·4–100]) | 150/154 (97% [93·5–99·3]) |
| Three f-IPV group at week 18 after two doses | 134/161 (83% [76·5–88·6]) | 135/161 (84% [77·2–89·2]) | 118/161 (73% [65·8–79·9]) |
| Three f-IPV group at week 40 after three doses | 158/160 (99% [95·6–99·8]) | 160/160 (100% [97·7–100]) | 150/160 (94% [88·8–97·0]) |
| Two f-IPV group at week 40 after two doses | 186/194 (96% [92·0–98·2]) | 190/194 (98% [94·8–99·4]) | 164/194 (85% [78·7–89·3]) |
Data are n (%) unless otherwise specified. The three IPV group received intramuscular vaccine at 10, 14, and 36 weeks. The two IPV group received intramuscular vaccine at 14 and 36 weeks. The three f-IPV group received intradermal vaccine at 10, 14, and 36 weeks. The two f-IPV group received intradermal vaccine at 14 and 36 weeks. f-IPV was one-fifth of a normal IPV dose. IPV=inactivated poliovirus vaccine. f-IPV=fractional inactivated poliovirus vaccine.